Company profile: PT Theragnostic
1.1 - Company Overview
Company description
- Provider of genomics-based personalized analysis for radiation sensitivity.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to PT Theragnostic
NMS Group
HQ: Italy
Website
- Description: Provider of oncology research and development, managing the integrated R&D chain from pre-clinical to clinical stages. Operates a validated oncology drug discovery platform generating a pipeline of new chemical entities (NCEs).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NMS Group company profile →
Accent Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical oncology therapeutics developing first-in-class DHX9 inhibitors for cancers including those with BRCA loss and mismatch repair deficiencies; potential best-in-class KIF18A inhibitors for multiple indications including ovarian and triple-negative breast cancer; first-in-class small molecule ADAR1 inhibitors for solid tumors; and XRN1 inhibitors for tumors with higher IFN signaling, as monotherapies and with immuno-oncology therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Accent Therapeutics company profile →
Dragonfly Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage immunotherapies harnessing the innate and adaptive immune systems. Offers the TriNKET platform for tri-specific immune engagers and a CYTOKINE platform for cytokine-based therapies for cancer and other diseases. Pipeline includes DF1001 (HER2, solid tumors), DF9001 (EGFR, solid tumors), DF6215 (IL-2, advanced solid tumors), and DF6002 (IL-12, extended half-life) for cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dragonfly Therapeutics company profile →
Cristal Therapeutics
HQ: The Netherlands
Website
- Description: Provider of nanomedicine and bioconjugation technologies based on proprietary polymeric platforms. Offers CriPec, a nanomedicine platform for targeted treatment of cancer and other diseases with patient stratification via non-invasive imaging; CliCr, copper-free click chemistry for stable bioconjugates; and CriVac, a vaccine platform combining CliCr with OMV, including for SARS-CoV-2.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cristal Therapeutics company profile →
Transgene
HQ: France
Website
- Description: Provider of integrated immunotherapies to treat cancers and chronic infectious diseases, covering research, clinical batch manufacturing, and clinical trials. Portfolio includes TG4050 personalized neoantigen cancer vaccine using genetic engineering and AI; TG4001 therapeutic HPV-16 cancer vaccine; BT-001 (anti-CTLA4, GM-CSF) and TG6050 (IL-12, anti-CTLA4) oncolytic viruses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Transgene company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for PT Theragnostic
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to PT Theragnostic
2.2 - Growth funds investing in similar companies to PT Theragnostic
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for PT Theragnostic
4.2 - Public trading comparable groups for PT Theragnostic
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →